Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
J&J reports 12-month data for Varipulse PFA platform
Johnson & Johnson (J&J) has reported interim 12-month results from the VARIPURE study, assessing the effectiveness and safety of its …
-
Vir Biotechnology doses first patient in Phase I VIR-5500 trial
Vir Biotechnology has dosed the first patient in one of three expansion cohorts in its ongoing Phase I clinical trial …
-
MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority
Merck & Co (MSD) and Daiichi Sankyo have received priority review from the US Food and Drug Administration (FDA) for …
-
Zebra Technologies and Aiva Health team up on nurse solutions
Zebra Technologies and Aiva Health have collaborated to support hands-free nurse workflows with Aiva's AI-powered solution. This partnership integrates Aiva’s AI-based …
-
FDA issues complete response letter to Replimune’s RP1 for melanoma
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Replimune Group’s biologics licence application …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
BioNTech and DualityBio report positive data for trastuzumab pamirtecan
BioNTech and DualityBio reported encouraging data from a Phase II cohort of their global clinical study evaluating the efficacy of …
-
GE HealthCare and Medtronic integrate bkActiv iUS and Stealth AXiS system
GE HealthCare has integrated its bkActiv intraoperative ultrasound (iUS) system with Medtronic's Stealth AXiS surgical navigation system to provide imaging …
-
AllRock Bio begins patient dosing in Phase IIa ROCSTAR trial
AllRock Bio has dosed the first patients in the Phase IIa ROCSTAR clinical trial investigating ROC-101, an oral pan-rho-associated protein …
-
Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation
Gan & Lee Pharmaceuticals has entered an exclusive licence agreement with JW Pharmaceutical for the clinical development, regulatory approval, and …
-
MHRA secures $4.8m to expand AI medical device programme
The Medicines and Healthcare products Regulatory Agency (MHRA) has secured a £3.6m ($4.8m) funding increase over three years to expand …
-
Hemispherian begins Phase I/IIa trial of GLIX1 for GBM
Hemispherian has initiated a first-in-human Phase I/IIa trial of its oral small molecule, GLIX1, in patients with recurrent and progressive …
-
Jeito Capital secures over $1.2bn for new biopharma investments
Global independent private equity fund Jeito Capital has closed its second fund, Jeito II, surpassing its target of €1bn ($1.2bn), …
-
J&J advances PFA portfolio with Varipulse Pro launch in Europe
Johnson & Johnson (J&J) has launched Varipulse Pro in Europe after securing CE Mark approval, strengthening its pulsed field ablation …
-
First patient dosed in CatalYm’s Phase IIb visugromab trial
CatalYm has dosed the first patient in its Phase IIb GDFATHER-HCC-01 clinical trial, assessing visugromab, along with chemoimmunotherapy as a …
-
Halozyme and Vertex sign deal for Hypercon technology
Halozyme Therapeutics' subsidiary Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for the former's …
